BioStar Capital Research
Investment Thesis
BioStar Capital is a physician-founded venture capital firm that positions itself as a "value-add investor in transformational medical technologies." Founded in 2005 by Dr. Louis A. Cannon, a nationally recognized interventional cardiologist, the firm combines clinical expertise with financial acumen to identify and back high-impact healthcare device innovations. Its stated mission is "to make a difference in patients' lives while providing returns for our investors." The firm's differentiator is its network of over 100 practicing physicians and "Medical Venture Partners" (MVPs) — healthcare clinicians, executives, and FDA experts — who evaluate deals for clinical significance, novelty, market acceptance likelihood, and competitive advantage before capital is committed.
Sector Focus
BioStar concentrates on medical technology, with explicit emphasis on cardiovascular disease, orthopedics, and robotics. Within those verticals it favors "smart" devices and robotics, minimally invasive procedures, cost-reduction technology, access-improvement technology, and outpatient-center-compatible technology. The current active portfolio is dominated by structural heart, vascular intervention, and robotic surgery platforms (e.g., pulsed field ablation, intravascular lithotripsy, robotic microsurgery, polymer heart valves).
Stage Focus
BioStar's own materials describe investments "spanning early and late-stage opportunities" across its five funds. In practice, recent disclosed rounds cluster at Series B through Series D (Nectero Medical's $96M Series D, AVS's $36M Series B, Versa Vascular's $27.3M Series C, Field Medical's $35M Series B, Ablative Solutions' Series D tranche), suggesting the firm is most active as a growth-stage medtech investor rather than a true seed fund, though it has been involved with companies since early rounds (e.g., AVS since its 2018 founding era).
Check Size
No specific check-size range is disclosed publicly. Given round sizes the firm participates in ($20M–$96M rounds), individual checks are likely in the low-to-high single-digit millions for a syndicate position, scaling with round size and BioStar's role.
Lead Tendency
Not explicitly disclosed. BioStar is consistently named among the investor group in press releases for portfolio financings but does not always identify as the round lead, so lead tendency is marked "unknown."
Recent Activity
BioStar closed its fifth fund, Fund V, at $130.3 million in December 2023, surpassing the size of its prior funds. The firm has been highly active in 2024–2026:
- January 2025: AVS closed a $36M Series B ahead of its U.S. commercial IVL launch.
- April 2024: Nectero Medical completed a $96M Series D.
- September 2025: Versa Vascular raised an oversubscribed $27.3M Series C and named David Hovda as CEO.
- May 2026: Portfolio company Amplitude Vascular Systems (AVS) was acquired by Stryker in a deal worth up to $835M — one of the largest medtech exits out of Michigan in recent years, and the fund's most prominent recent liquidity event.
Portfolio Highlights
Active portfolio includes Ablative Solutions (transcatheter renal denervation), Aria CV (pulmonary hypertension implant), Field Medical (pulsed field ablation for ventricular tachycardia), Foldax (robotically manufactured polymer heart valves), Micro Medical Instruments/MMI (robotic microsurgery, Symani Surgical System — named a TIME Best Invention of 2024 and a Fast Company Most Innovative Company in 2023), Nectero Medical (endovascular AAA stabilization therapy), Olympic Ophthalmics (dry eye neurostimulation device), Reva Medical (bioresorbable vascular scaffolds), and Versa Vascular (percutaneous tricuspid valve repair).
Notable historical exits include Amplitude Vascular Systems (acquired by Stryker, up to $835M, 2026), V-Wave (acquired by Johnson & Johnson, up to $1.7B, 2024), Corindus Vascular Robotics (acquired by Siemens Healthineers, $1.1B, 2019), and CathWorks (option to acquire signed by Medtronic, up to $585M, 2022) — a track record that spans robotic vascular intervention, heart-failure devices, and AI-powered coronary imaging.
Team
BioStar's team blends clinicians, operators, and finance professionals:
- Louis Cannon, MD — Founder, Senior Managing Director; nationally recognized interventional cardiologist who conceived the lithotripsy thesis while on the University of Michigan's Coulter Committee.
- Mark Toland — Managing Director.
- Ben Cannon — Growth Equity, Partner & Advisor.
- Alan Davis, MD — Managing Director.
- Steven Yakubov, MD — Director.
- Jason Johnson — CFO.
- William H. "Hank" Kucheman — Managing Director.
- Jeremy Touroo — Director.
- Sarah Petrowski — Executive Assistant.
Individual biographical detail (education, prior operating roles) was not exposed on the public team page beyond names and titles.
Decision Process
BioStar describes a "comprehensive evaluation" process run jointly by its leadership team and its network of Medical Venture Partners — practicing physicians who assess clinical impact, IP strength, capital requirements, and likely acquirers before an investment is made. This structured, physician-informed diligence process resembles an investment-committee model more than a solo-GP or lightweight partnership sign-off.
Founder Preferences
BioStar looks for companies addressing clear "unmet patient needs" within cardiovascular, orthopedic, and robotics device categories, and leans on its clinician network and relationships with leading research centers (e.g., University of Michigan) to source deal flow. It appears comfortable backing founding teams built around physician-inventors as well as professional medtech operators.
Geographic Focus
BioStar is headquartered in Michigan (offices in Charlevoix, MI and Rocky River, OH), and has been described in local press as anchoring Michigan's medtech ecosystem, but its portfolio companies are geographically dispersed across the U.S. (Massachusetts, Texas, California, and elsewhere), indicating no strict regional investment mandate despite the firm's Midwest roots.
Notes on Ranking Context
BioStar Capital appears on the 2026 Strebulaev-Jackson venture capital ranking as the #48 firm in the Biotech category, reflecting its consistent track record of large medtech exits (Stryker, J&J, Siemens Healthineers, Medtronic) over two decades of physician-led investing.